Why Regeneron Pharmaceuticals, Inc. (REGN) stock moved
Regeneron Pharmaceuticals, Inc. (REGN) shares climbed 11.5% to $913.12 as of October 30, 2026, a sharp gain from the prior close of $818.77. BestStocks flagged the session as a major change for REGN. The move is tied to an earnings beat. Below, we break down what changed for REGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
Regeneron Pharmaceuticals, Inc. (REGN) reported EPS of $20.07 vs. consensus estimate of $16.42, beating by 22.2%. REGN's next earnings report is scheduled for January 29, 2027, with a consensus EPS estimate of $20.87.
What it means for Regeneron Pharmaceuticals, Inc. investors
For Regeneron Pharmaceuticals, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Strong 11.5% price move with conviction. Weighing against that: Regeneron and Sanofi announced an expansion of their alliance valued at up to $8 billion to develop next-generation, long-acting immunology antibodies alongside their existing DUPIXENT collaboration, according to Globe Newswire and the Wall Street Journal; Regeneron Pharmaceuticals, Inc. moved -3.37% intraday from $788.04 to $761.46. Wall Street's consensus price target sits at $853.63, implying -6.5% downside from $913.12. Over the past 90 days analysts logged 2 upgrades and 0 downgrades. BestStocks rates the overall signal quality high (83/100). With earnings roughly 91 days out, the next report is the most likely near-term test of the move.
REGN price reaction
REGN last traded at $913.12, up $94.35 (+11.52%) from the previous close of $818.77. The session traded on 2.1× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $726.47 and $913.12, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Regeneron Pharmaceuticals, Inc. (REGN)
The consensus analyst price target on Regeneron Pharmaceuticals, Inc. (REGN) is $853.63, 6.5% below the recent $913.12. Over the past 90 days analysts logged 2 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on REGN line up.
The bullish case
- The Street's most bullish target is $1,030.00 (+12.8%).
- 2 analyst upgrades in the past 90 days, most recently UBS to Buy (2026-10-15).
- Earnings beat with positive market reaction.
- Strong 11.5% price move with conviction.
- Volume 2.1x average — institutional conviction.
The bearish case
- The consensus analyst price target of $853.63 sits 6.5% below the recent $913.12, so the average target sees limited room to run.
- The most bearish analyst target is $750.00 (-17.9%).
- Regeneron and Sanofi announced an expansion of their alliance valued at up to $8 billion to develop next-generation, long-acting immunology antibodies alongside their existing DUPIXENT collaboration, according to Globe Newswire and the Wall Street Journal.
- Regeneron Pharmaceuticals, Inc. moved -3.37% intraday from $788.04 to $761.46.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for REGN
Frequently asked questions about REGN
Why did Regeneron Pharmaceuticals, Inc. (REGN) stock move?
REGN climbed 11.5% to $913.12. The move is associated with an earnings beat.
How much did REGN stock rise?
REGN gained 11.52% ($94.35) versus the prior close of $818.77, last trading at $913.12 on 2.1× average volume.
When is Regeneron Pharmaceuticals, Inc.'s next earnings date?
REGN's next earnings report is estimated for 2027-01-29 — about 91 days away.
What is the analyst price target for REGN?
The consensus analyst price target for REGN is $853.63, about 6.5% below the current $913.12. Over the past 90 days, analysts recorded 2 upgrades, 13 maintains, and 0 downgrades.
How BestStocks tracks REGN
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for REGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.